Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
$0.89
+0.5%
$1.01
$0.66
$17.75
$5.37M0.22796,311 shs92,564 shs
Imunon, Inc. stock logo
CLSN
Imunon
$2.22
$1.80
$15.75
$13.91M2.27150,471 shs711 shs
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
$36.44
+0.5%
$35.99
$1.72
$54.30
$223.01M1.01360,787 shs15,256 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.36
+0.8%
$0.78
$0.30
$4.28
$17.38M-0.061.35 million shs1.15 million shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
0.00%+7.59%-14.13%+12.38%-42.76%
Imunon, Inc. stock logo
CLSN
Imunon
0.00%0.00%0.00%0.00%0.00%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
0.00%+6.76%-3.34%+24.16%+896.25%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
0.00%+9.04%-55.20%-38.67%-68.55%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
0.5755 of 5 stars
0.05.00.00.00.60.00.6
Imunon, Inc. stock logo
CLSN
Imunon
N/AN/AN/AN/AN/AN/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
3.0466 of 5 stars
3.45.00.00.02.81.70.0
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
2.2731 of 5 stars
3.61.00.00.00.63.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
0.00
N/AN/AN/A
Imunon, Inc. stock logo
CLSN
Imunon
0.00
N/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
2.83
Moderate Buy$60.0064.65% Upside
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
3.29
Buy$9.002,379.34% Upside

Current Analyst Ratings Breakdown

Latest CLSN, MNPR, ATNF, and RVPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$74.00
6/27/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
6/27/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
6/23/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
6/11/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
6/3/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
5/24/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/20/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $3.00
5/10/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
4/24/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
4/24/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/AN/AN/AN/A$2.91 per shareN/A
Imunon, Inc. stock logo
CLSN
Imunon
$500K0.00N/AN/A$9.66 per share0.00
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/A$9.02 per shareN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/A$0.02 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
-$6.17MN/A0.00N/AN/A-147.32%-76.99%8/11/2025 (Estimated)
Imunon, Inc. stock logo
CLSN
Imunon
-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$15.59M-$3.48N/AN/AN/AN/A-55.39%-51.53%8/8/2025 (Estimated)
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$29.92M-$0.79N/AN/AN/AN/AN/A-302.31%8/13/2025 (Estimated)

Latest CLSN, MNPR, ATNF, and RVPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/A-$0.67N/A-$0.67N/AN/A
5/15/2025Q1 2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.21-$0.13+$0.08-$0.13N/AN/A
5/13/2025Q1 2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$0.65-$0.38+$0.27-$0.38N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/AN/AN/AN/AN/A
Imunon, Inc. stock logo
CLSN
Imunon
N/AN/AN/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/A
1.02
1.02
Imunon, Inc. stock logo
CLSN
Imunon
0.13
6.52
6.52
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/A
36.91
36.91
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/A
0.54
0.54

Institutional Ownership

CompanyInstitutional Ownership
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
4.07%
Imunon, Inc. stock logo
CLSN
Imunon
12.97%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
1.83%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
63.18%

Insider Ownership

CompanyInsider Ownership
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
0.17%
Imunon, Inc. stock logo
CLSN
Imunon
4.66%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
20.50%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
27.18%
CompanyEmployeesShares OutstandingFree FloatOptionable
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
76.07 million6.06 millionNo Data
Imunon, Inc. stock logo
CLSN
Imunon
277.10 million6.77 millionOptionable
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
106.12 million4.86 millionNot Optionable
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
548.00 million34.96 millionOptionable

Recent News About These Companies

Reviva Pharmaceuticals Holdings, Inc. (RVPHW) - Yahoo Finance
Reviva Dives on Stock Offering
RVPH: M&A Deals Highlight Brilaroxazine Value

New MarketBeat Followers Over Time

Media Sentiment Over Time

180 Life Sciences stock logo

180 Life Sciences NASDAQ:ATNF

$0.88 +0.00 (+0.50%)
As of 10:59 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Imunon stock logo

Imunon NASDAQ:CLSN

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

Monopar Therapeutics stock logo

Monopar Therapeutics NASDAQ:MNPR

$36.44 +0.19 (+0.52%)
As of 10:59 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Reviva Pharmaceuticals stock logo

Reviva Pharmaceuticals NASDAQ:RVPH

$0.36 +0.00 (+0.83%)
As of 10:58 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.